DE122008000018I1 - Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica - Google Patents

Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica

Info

Publication number: DE122008000018I1
Authority: DE; Germany
Prior art keywords: inhibitors; insulin; glucose; fructose; nvp
Prior art date: 2000-01-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

DE122008000018C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Pharma AG

Original Assignee

Novartis Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2001-01-19

Publication date

2008-08-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049636&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122008000018(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-19 Application filed by Novartis Pharma AG filed Critical Novartis Pharma AG

2008-08-14 Publication of DE122008000018I1 publication Critical patent/DE122008000018I1/de

Status Pending legal-status Critical Current

Links

230000003178 anti-diabetic effect Effects 0.000 title abstract 2
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 abstract 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
208000002705 Glucose Intolerance Diseases 0.000 abstract 2
102000003638 Glucose-6-Phosphatase Human genes 0.000 abstract 2
108010086800 Glucose-6-Phosphatase Proteins 0.000 abstract 2
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract 2
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 2
102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 abstract 2
101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 abstract 2
239000003623 enhancer Substances 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
201000009104 prediabetes syndrome Diseases 0.000 abstract 2
108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 2
SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 2
VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 abstract 1
208000010444 Acidosis Diseases 0.000 abstract 1
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 abstract 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
102000027487 Fructose-Bisphosphatase Human genes 0.000 abstract 1
108010017464 Fructose-Bisphosphatase Proteins 0.000 abstract 1
229940122904 Glucagon receptor antagonist Drugs 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000007976 Ketosis Diseases 0.000 abstract 1
206010027417 Metabolic acidosis Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000674 adrenergic antagonist Substances 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
206010003246 arthritis Diseases 0.000 abstract 1
230000030136 gastric emptying Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
230000009229 glucose formation Effects 0.000 abstract 1
230000002440 hepatic effect Effects 0.000 abstract 1
230000001771 impaired effect Effects 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
230000004140 ketosis Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
229930029653 phosphoenolpyruvate Natural products 0.000 abstract 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
150000003384 small molecules Chemical class 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
229960001254 vildagliptin Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DE122008000018C 2000-01-21 2001-01-19 Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica Pending DE122008000018I1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48923400A	2000-01-21	2000-01-21
US61926200A	2000-07-19	2000-07-19

Publications (1)

Publication Number	Publication Date
DE122008000018I1 true DE122008000018I1 (de)	2008-08-14

Family

ID=27049636

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DE60132723T Expired - Lifetime DE60132723T2 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
DE122008000018C Pending DE122008000018I1 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
DE60124861T Expired - Lifetime DE60124861T2 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE60132723T Expired - Lifetime DE60132723T2 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60124861T Expired - Lifetime DE60124861T2 (de)	2000-01-21	2001-01-19	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica

Country Status (17)

Country	Link
US (1)	US20030139434A1 (de)
EP (5)	EP1248604B2 (de)
JP (7)	JP2003520226A (de)
CN (3)	CN102327614A (de)
AT (2)	ATE346613T1 (de)
AU (1)	AU2001237321A1 (de)
BR (1)	BRPI0107715B8 (de)
CA (2)	CA2673615C (de)
CY (6)	CY1106303T1 (de)
DE (3)	DE60132723T2 (de)
DK (5)	DK1741446T3 (de)
ES (5)	ES2275654T5 (de)
FR (1)	FR08C0017I2 (de)
LU (1)	LU91436I2 (de)
NL (1)	NL300346I1 (de)
PT (5)	PT1743655E (de)
WO (1)	WO2001052825A2 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2684168B2 (ja)	1995-10-30	1997-12-03	トーワ株式会社	離型抵抗力測定方法及び測定装置
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
EP1112275B9 (de)	1998-09-09	2004-03-10	Metabasis Therapeutics, Inc.	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
EP1113804A2 (de) *	1998-09-17	2001-07-11	Akesis Pharmaceuticals, Inc.	Kombinationen des chroms oder des vanadiums mit antidiabetika für glukosemetabolismusstörungen
DK1741446T3 (da) *	2000-01-21	2008-06-02	Novartis Pharma Ag	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
PL357251A1 (en)	2000-03-08	2004-07-26	Metabasis Therapeutics, Inc.	Novel aryl fructose-1,6-bisphosphatase inhibitors
US7078397B2 (en)	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB0014969D0 (en) *	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7563774B2 (en)	2000-06-29	2009-07-21	Metabasis Therapeutics, Inc.	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
CZ20035A3 (cs) *	2000-07-06	2003-05-14	Metabasis Therapeutics, Inc.	Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
CN1847229B (zh) *	2000-10-23	2011-05-04	史密丝克莱恩比彻姆公司	2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
WO2003002553A2 (en)	2001-06-27	2003-01-09	Smithkline Beecham Corporation	Fluoropyrrolidines as dipeptidyl peptidase inhibitors
ATE374181T1 (de)	2001-06-27	2007-10-15	Smithkline Beecham Corp	Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
DE60223920T2 (de)	2001-06-27	2008-11-13	Smithkline Beecham Corp.	Pyrrolidine als dipeptidyl-peptidase-inhibitoren
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
US7524885B2 (en) *	2002-04-01	2009-04-28	The Governors Of The University Of Alberta	Compounds that stimulate glucose utilization and methods of use
GB0212412D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Combination of organic compounds
ATE422884T1 (de) *	2002-06-03	2009-03-15	Novartis Pharma Gmbh	Verwendung von substituierten cyanopyrrolidinen zur behandlung von hyperlipidämie
EA016166B1 (ru) *	2002-08-21	2012-02-28	Бёрингер Ингельхайм Фарма Гмбх & Ко. Кг	8-[3-аминопиперидин-1-ил]ксантины, способ их получения и их применение в качестве лекарственных средств
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7648957B2 (en) *	2002-09-04	2010-01-19	Dsm Ip Assets B.V.	Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
US20060094722A1 (en) *	2002-09-26	2006-05-04	Eisai Co., Ltd.	Combination drug
WO2004052362A1 (en) *	2002-12-10	2004-06-24	Novartis Ag	Combination of an dpp-iv inhibitor and a ppar-alpha compound
US20040242566A1 (en) *	2003-03-25	2004-12-02	Syrrx, Inc.	Dipeptidyl peptidase inhibitors
EP1625122A1 (de)	2003-05-14	2006-02-15	Takeda San Diego, Inc.	Dipeptidylpeptidase-hemmer
WO2005000299A1 (en) *	2003-06-27	2005-01-06	Dr. Reddy's Research Foundation	Compositions comprising balaglitazone and further antidiabetic compounds
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CA2535619A1 (en)	2003-08-13	2005-02-24	Takeda Pharmaceutical Company Limited	4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
CA2536432A1 (en) *	2003-09-02	2005-03-10	Prosidion Limited	Combination therapy for glycaemic control
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
KR20130105741A (ko)	2003-11-17	2013-09-25	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
US20070149451A1 (en) *	2003-11-17	2007-06-28	Holmes David G	Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
BR122018014389B1 (pt)	2004-01-20	2023-04-25	Novartis Ag	Processo para preparar comprimido farmacêutico por compressão direta
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
GEP20094679B (en)	2004-03-15	2009-05-10	Takeda Pharmaceuticals Co	Dipeptidyl peptidase inhibitors
JP2007261945A (ja) *	2004-04-07	2007-10-11	Taisho Pharmaceut Co Ltd	チアゾール誘導体
US7829720B2 (en)	2004-05-04	2010-11-09	Bristol-Myers Squibb Company	Process for preparing atazanavir bisulfate and novel forms
TWI354569B (en) *	2004-05-28	2011-12-21	Bristol Myers Squibb Co	Coated tablet formulation and method
US7687638B2 (en)	2004-06-04	2010-03-30	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7935723B2 (en)	2004-06-04	2011-05-03	Novartis Pharma Ag	Use of organic compounds
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
CN101087756B (zh)	2004-07-23	2011-04-06	纽阿达有限责任公司	肽酶抑制剂
US20070259927A1 (en) *	2004-08-26	2007-11-08	Takeda Pharmaceutical Company Limited	Remedy for Diabetes
US20090253752A1 (en) *	2004-10-25	2009-10-08	Bryan Burkey	Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7872124B2 (en)	2004-12-21	2011-01-18	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
DOP2006000008A (es)	2005-01-10	2006-08-31	Arena Pharm Inc	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CN101332303B (zh) *	2005-01-10	2012-09-26	艾尼纳制药公司	用于治疗糖尿病和其相关病状以及用于治疗通过增加血液glp-1水平而改善的病状的组合疗法
CN101495475A (zh) *	2005-03-25	2009-07-29	葛兰素集团有限公司	制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
UY29440A1 (es)	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
ES2477868T3 (es)	2005-04-22	2014-07-18	Alantos Pharmaceuticals Holding, Inc.	Inhibidores de dipeptidil peptidasa-IV
JP2008115080A (ja) *	2005-04-22	2008-05-22	Taisho Pharmaceutical Co Ltd	併用医薬
KR101438234B1 (ko) *	2005-06-03	2014-09-04	미쓰비시 타나베 파마 코퍼레이션	의약의 병용 및 그 용도
MY152185A (en) *	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
EP1898931B1 (de) *	2005-07-07	2014-12-31	Postech Foundation	Glucose-aufnahmemodulator und verfahren zur behandlung von diabetes oder diabetischen komplikationen
CN101222919A (zh) *	2005-07-12	2008-07-16	诺瓦提斯公司	Dpp-ⅳ抑制剂与大麻素受体-1（cb1）拮抗物的组合
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ME02005B (me)	2005-09-14	2012-08-31	Takeda Pharmaceuticals Co	Inhibitori dipeptidil peptidaze za lečenje dijabetesa
CN101360723A (zh)	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
JP5072848B2 (ja) *	2005-09-20	2012-11-14	ノバルティスアーゲー	低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
JOP20180109A1 (ar) *	2005-09-29	2019-01-30	Novartis Ag	تركيبة جديدة
TW200738266A (en) *	2005-09-29	2007-10-16	Sankyo Co	Pharmaceutical agent containing insulin resistance improving agent
CN101272780A (zh) *	2005-09-30	2008-09-24	诺瓦提斯公司	用于自身免疫疾病和移植排斥治疗的dpp iv抑制剂
CA2625150A1 (en) *	2005-10-07	2007-04-19	Waratah Pharmaceuticals, Inc.	Combined use of dpp-iv inhibitors and gastrin compounds
BRPI0620718A2 (pt) *	2005-10-28	2011-11-22	Takeda Pharmaceutical	agente para a proteção do páncreas, e, uso de uma droga para a redução de glicose
EP1962827A4 (de) *	2005-12-16	2011-02-16	Merck Sharp & Dohme	Pharmazeutische zusammensetzungen von kombinationen von dipeptidyl-peptidase-4-hemmern mit metformin
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
PE20071221A1 (es)	2006-04-11	2007-12-14	Arena Pharm Inc	Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US7833730B2 (en)	2006-04-11	2010-11-16	Arena Pharmaceuticals, Inc.	Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
KR101452915B1 (ko)	2006-05-04	2014-10-21	베링거 인겔하임 인터내셔날 게엠베하	다형태
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
DK2073810T3 (da) *	2006-09-13	2011-10-31	Takeda Pharmaceutical	Anvendelse af 2-6-(3-aminio-piperidin-l-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-l-ylmethyl-4-fluor-benzonitril til behandling af diabetes, cancer, autoimmune sygdomme og HIV infektion
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
JP2010043002A (ja) *	2006-11-27	2010-02-25	Ajinomoto Co Inc	糖尿病治療剤
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
EA015180B1 (ru)	2007-02-01	2011-06-30	Такеда Фармасьютикал Компани Лимитед	Твердый препарат, содержащий алоглиптин и пиоглитазон
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es) *	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20140960A1 (es)	2008-04-03	2014-08-15	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
EP2146210A1 (de)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
PL2275108T3 (pl) *	2008-05-14	2015-01-30	Sanwa Kagaku Kenkyusho Co	Preparat farmaceutyczny zawierający inhibitor dpp-iv i inny terapeutyczny środek na cukrzycę w postaci stosowanej równocześnie lub w postaci połączonej
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko)	2008-08-06	2019-02-18	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
MX2011002558A (es)	2008-09-10	2011-04-26	Boehringer Ingelheim Int	Terapia de combinacion para el tratamiento de diabetes y estados relacionados.
AR074797A1 (es) *	2008-10-10	2011-02-16	Japan Tobacco Inc	Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010062863A2 (en) *	2008-11-26	2010-06-03	Satiogen Pharmaceuticals, Inc.	Compositions containing satiogens and methods of use
CN102316872B (zh)	2008-11-26	2016-12-21	萨蒂奥根制药公司	治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
WO2010071750A1 (en) *	2008-12-19	2010-06-24	Merck Sharp & Dohme Corp.	Glucagon receptor antagonist compounds
AU2009331471B2 (en)	2008-12-23	2015-09-03	Boehringer Ingelheim International Gmbh	Salt forms of organic compound
WO2010074271A1 (ja) *	2008-12-26	2010-07-01	武田薬品工業株式会社	糖尿病治療剤
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PT2395983T (pt)	2009-02-13	2020-07-03	Boehringer Ingelheim Int	Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
AR077642A1 (es)	2009-07-09	2011-09-14	Arena Pharm Inc	Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
CA2793836C (en)	2009-10-21	2020-03-24	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en)	2009-10-21	2011-04-28	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
KR20120107080A (ko)	2009-11-27	2012-09-28	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011080276A1 (en)	2009-12-29	2011-07-07	Genfit	Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative
JP2013523819A (ja)	2010-04-06	2013-06-17	アリーナファーマシューティカルズ，インコーポレイテッド	Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
KR101927068B1 (ko)	2010-05-05	2018-12-10	베링거 인겔하임 인터내셔날 게엠베하	체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
EP4137137A1 (de)	2010-05-26	2023-02-22	Satiogen Pharmaceuticals, Inc.	Gallensäurerecyclinghemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
KR20220025926A (ko)	2010-06-24	2022-03-03	베링거 인겔하임 인터내셔날 게엠베하	당뇨병 요법
EP2619198A1 (de)	2010-09-22	2013-07-31	Arena Pharmaceuticals, Inc.	Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20140018371A1 (en)	2011-04-01	2014-01-16	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en)	2011-04-22	2012-10-26	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103781788B (zh)	2011-07-15	2016-08-17	勃林格殷格翰国际有限公司	经取代的喹唑啉、其制备及其在药物组合物中的用途
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
PT2771003T (pt)	2011-10-28	2017-07-26	Lumena Pharmaceuticals Llc	Inibidores da reciclagem de ácidos biliares para tratamento de doenças hepáticas colestáticas pediátricas
EP2770990A4 (de)	2011-10-28	2015-03-11	Lumena Pharmaceuticals Inc	Gallensäurerückflusshemmer zur behandlung von hypercholämie und cholestatischer lebererkrankung
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EA021236B1 (ru) *	2012-10-03	2015-05-29	Дафот Энтерпраизес Лимитед	Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
JP6615109B2 (ja)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｄｐｐ−４阻害薬の医学的使用
EP3267994A4 (de)	2015-03-09	2018-10-31	Intekrin Therapeutics, Inc.	Verfahren zur behandlung von nichtalkoholischer fettlebererkrankung und/oder lipodystrophie
MX390363B (es)	2016-06-10	2025-03-20	Boehringer Ingelheim Int	Combinacion de linagliptina y metformina
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
SG11201909046XA (en)	2017-04-03	2019-10-30	Coherus Biosciences Inc	PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
EP4335438A1 (de)	2019-09-17	2024-03-13	Novartis AG	Kombinationstherapie mit vildagliptin und metformin

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US489795A (en)		1893-01-10		Steadying device for portable engines
US988496A (en)	1910-09-19	1911-04-04	Henry Obermann	Ventilator.
US4062950A (en)	1973-09-22	1977-12-13	Bayer Aktiengesellschaft	Amino sugar derivatives
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
US4342771A (en) *	1981-01-02	1982-08-03	Pfizer Inc.	Hypoglycemic 5-substituted oxazolidine-2,4-diones
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
DE3347565A1 (de)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5216167A (en) *	1983-12-30	1993-06-01	Dr. Karl Thomae Gmbh	Phenylacetic acid benzylamides
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
HU210339B (en)	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
DE3543999A1 (de)	1985-12-13	1987-06-19	Bayer Ag	Hochreine acarbose
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5071773A (en)	1986-10-24	1991-12-10	The Salk Institute For Biological Studies	Hormone receptor-related bioassays
EP0306228B1 (de)	1987-09-04	1999-11-17	Beecham Group Plc	Substituierte Thiazolidindionderivate
US4981784A (en)	1987-12-02	1991-01-01	The Salk Institute For Biological Studies	Retinoic acid receptor method
WO1989008651A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Hypoglycemic thiazolidinedione derivatives
JPH05504254A (ja)	1989-10-25	1993-07-08	ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ	レセプター感染アッセイ
US4997948A (en)	1989-10-27	1991-03-05	American Home Products	5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
EP0441483A3 (en)	1990-01-16	1992-11-19	Baylor College Of Medicine	Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
ATE164852T1 (de)	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
CA2090407A1 (en)	1990-09-21	1992-03-22	Ronald M. Evans	Functional antagonism between proto-oncoprotein c-jun and hormone receptors
DE10199058I2 (de)	1991-07-30	2006-04-27	Alcm Co	Kristalle von N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
US5866563A (en)	1991-09-30	1999-02-02	The University Of British Columbia	Vanadium compositions
EP1396541A3 (de)	1991-12-06	2004-11-24	The Salk Institute For Biological Studies	Multimere von Mitgliedern der Thyroid/Steroid- Superfamilie von Rezeptoren
AU679171B2 (en)	1991-12-18	1997-06-26	Baylor College Of Medicine	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
PT637297E (pt)	1992-04-22	2001-01-31	Ligand Pharm Inc	Compostos com selectividade para os receptores de retinoide x
JPH07509694A (ja)	1992-05-14	1995-10-26	ベイラー・カレッジ・オブ・メディシン	突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5466861A (en)	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
JP2845743B2 (ja)	1992-12-28	1999-01-13	三菱化学株式会社	新規なナフタレン誘導体
EP0678087B1 (de)	1993-01-11	1999-03-17	Ligand Pharmaceuticals, Inc.	Verbindungen mit selektiver wirkung fuer retinoid x rezeptoren, und mittel fuer steuerung fuer durch retinoid x rezeptoren bedingte prozesse
KR100306855B1 (ko)	1993-01-11	2001-11-30	윌리암 엘. 레스페스	레티노이드x수용체에대한선택성을갖는화합물
WO1994015901A1 (en)	1993-01-11	1994-07-21	Ligand Pharmaceuticals Inc.	Compounds having selectivity for retinoid x receptors
US5399586A (en)	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
CA2160135A1 (en)	1993-04-07	1994-10-13	Donald P. Mcdonnell	Method for screening for receptor agonists
US5506102A (en)	1993-10-28	1996-04-09	Ligand Pharmaceuticals Incorporated	Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
IL111785A0 (en) *	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
CA2182908A1 (en)	1993-12-30	1995-07-01	Ronald M. Evans	Uses for gal4-receptor constructs
US5705515A (en)	1994-04-26	1998-01-06	Merck & Co., Inc.	Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
DE4416433A1 (de)	1994-05-10	1995-11-16	Hoechst Ag	Cyclohexan-Derivate, Verfahren zu ihrer Herstellung und die Verwendung der Verbindungen zur Behandlung von Krankheiten
US5488510A (en)	1994-07-26	1996-01-30	Lemay; Edward J.	Enhanced depth perception viewing device for television
US5801253A (en)	1994-08-10	1998-09-01	Hoffmann-La Roche Inc.	Retinoic acid X-receptor ligands
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996020913A1 (en)	1994-12-30	1996-07-11	Ligand Pharmaceuticals Incorporated	Novel trienoic retinoid compounds and methods
CA2209134A1 (en)	1994-12-30	1996-07-11	Ligand Pharmaceuticals Incorporated	Tricyclic retinoids, methods for their production and use
DK0832066T3 (da)	1995-06-06	2001-11-19	Pfizer	Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
CA2224062C (en)	1995-06-06	2001-09-04	Pfizer Limited	Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
WO1997016442A1 (en)	1995-10-31	1997-05-09	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AU2090897A (en)	1996-02-29	1997-09-16	Mikael Bols	Hydroxyhexahydropyridazines
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
DE122010000020I1 (de) *	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
EP1019043A4 (de)	1996-05-07	2003-07-30	Univ Pennsylvania	Inhibitoren der glykogensynthese-kinase 3 und verfahren zu ihrer identifizierung und verwendung
AU712057B2 (en)	1996-06-07	1999-10-28	Merck & Co., Inc.	Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
ATE215369T1 (de)	1996-09-05	2002-04-15	Lilly Co Eli	Carbazolanaloge als selektive beta3-adrenergische agonisten
JP4010377B2 (ja)	1996-09-06	2007-11-21	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5776954A (en)	1996-10-30	1998-07-07	Merck & Co., Inc.	Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
FR2755439B1 (fr)	1996-11-05	1998-12-24	Virbac Sa	Derives aryloxypropanolamines, leur procede de preparation et leurs applications
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US5880139A (en)	1996-11-20	1999-03-09	Merck & Co., Inc.	Triaryl substituted imidazoles as glucagon antagonists
WO1998021957A1 (en)	1996-11-20	1998-05-28	Merck & Co., Inc.	Triaryl substituted imidazoles, compositions containing such compounds and methods of use
JP2001504489A (ja)	1996-11-20	2001-04-03	メルクエンドカンパニーインコーポレーテッド	トリアリール置換イミダゾール及び使用方法
EP0959886A4 (de)	1996-11-20	2001-05-02	Merck & Co Inc	Triaryl substituierte imidazole als glucagon antagonisten
US5952322A (en)	1996-12-05	1999-09-14	Pfizer Inc.	Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
CA2278739A1 (en)	1997-01-28	1998-07-30	Emma R. Parmee	Thiazole benzenesulfonamides as .beta.3 agonists for the treatment of diabetes and obesity
AU6691498A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel benzimidazole inhibitors of fructose-1,6-bisphosphatase
AU6290998A (en)	1997-03-07	1998-09-29	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
AU6691798A (en)	1997-03-07	1998-09-22	Metabasis Therapeutics, Inc.	Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6284748B1 (en)	1997-03-07	2001-09-04	Metabasis Therapeutics, Inc.	Purine inhibitors of fructose 1,6-bisphosphatase
AU749271B2 (en)	1997-07-01	2002-06-20	Agouron Pharmaceuticals, Inc.	Glucagon antagonists/inverse agonists
GB9715298D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
JP2001517670A (ja)	1997-09-23	2001-10-09	ノボノルディスクアクティーゼルスカブ	プロテインチロシンホスファターゼ（ＰＴＰａｓｅ）のモジュール
UA57811C2 (uk)	1997-11-21	2003-07-15	Пфайзер Продактс Інк.	Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
CA2312849A1 (en)	1997-12-05	1999-06-17	Charles David Jones	Selective .beta.3 adrenergic agonists
CA2819705C (en) *	1998-02-02	2014-07-08	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
AU2610299A (en)	1998-02-05	1999-08-23	Novo Nordisk A/S	Hydrazone derivatives
US5998463A (en)	1998-02-27	1999-12-07	Pfizer Inc	Glycogen phosphorylase inhibitors
HUP0102612A2 (hu)	1998-03-12	2001-11-28	Novo Nordisk A/S	Fehérje-tirozinfoszfatázokat moduláló vegyületek és ezeket tartalmazó gyógyászati készítmények
WO1999046267A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046236A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999046244A1 (en)	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
AU2825899A (en)	1998-03-12	1999-09-27	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
WO1999047549A1 (en)	1998-03-16	1999-09-23	Ontogen Corporation	PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
CN1208326C (zh)	1998-04-23	2005-06-29	雷迪实验室有限公司	杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
US6331633B1 (en)	1998-05-08	2001-12-18	Calyx Therapeutics Inc.	Heterocyclic analogs of diphenylethylene compounds
US6057316A (en)	1998-05-12	2000-05-02	American Home Products Corporation	4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
US6001867A (en)	1998-05-12	1999-12-14	American Home Products Corporation	1-aryl-dibenzothiophenes
DE69904318D1 (de)	1998-05-12	2003-01-16	Wyeth Corp	Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren
EP1077968A1 (de)	1998-05-12	2001-02-28	American Home Products Corporation	Naphto[2,3-b]heteroar-4-yl-derivate
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
EP0978279A1 (de)	1998-08-07	2000-02-09	Pfizer Products Inc.	Glycogen-phosphorylase inhibitoren
AU5154699A (en)	1998-09-02	2000-03-27	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno(2,3-c)pyridine derivatives
EP1112275B9 (de)	1998-09-09	2004-03-10	Metabasis Therapeutics, Inc.	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
HK1038564A1 (zh)	1998-10-08	2002-03-22	Smithkline Beecham Plc	用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮
CO5150173A1 (es) *	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6030837A (en)	1999-08-03	2000-02-29	Isis Pharmaceuticals Inc.	Antisense inhibition of PEPCK-mitochondrial expression
DK1741446T3 (da) *	2000-01-21	2008-06-02	Novartis Pharma Ag	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
TW200303742A (en) †	2001-11-21	2003-09-16	Novartis Ag	Organic compounds

2001
- 2001-01-19 DK DK06121895T patent/DK1741446T3/da active
- 2001-01-19 DK DK06121896.2T patent/DK1741447T3/da active
- 2001-01-19 ES ES01909661T patent/ES2275654T5/es not_active Expired - Lifetime
- 2001-01-19 PT PT61218988T patent/PT1743655E/pt unknown
- 2001-01-19 CA CA2673615A patent/CA2673615C/en not_active Expired - Lifetime
- 2001-01-19 AT AT01909661T patent/ATE346613T1/de active
- 2001-01-19 JP JP2001552873A patent/JP2003520226A/ja active Pending
- 2001-01-19 US US10/181,169 patent/US20030139434A1/en not_active Abandoned
- 2001-01-19 DE DE60132723T patent/DE60132723T2/de not_active Expired - Lifetime
- 2001-01-19 DK DK06121894.7T patent/DK1741445T3/da active
- 2001-01-19 WO PCT/EP2001/000590 patent/WO2001052825A2/en not_active Ceased
- 2001-01-19 CN CN2011102233943A patent/CN102327614A/zh active Pending
- 2001-01-19 ES ES06121898.8T patent/ES2487897T3/es not_active Expired - Lifetime
- 2001-01-19 ES ES06121896.2T patent/ES2436610T3/es not_active Expired - Lifetime
- 2001-01-19 AU AU2001237321A patent/AU2001237321A1/en not_active Abandoned
- 2001-01-19 PT PT01909661T patent/PT1248604E/pt unknown
- 2001-01-19 CN CNA2006101699199A patent/CN1977842A/zh active Pending
- 2001-01-19 EP EP01909661A patent/EP1248604B2/de not_active Expired - Lifetime
- 2001-01-19 ES ES06121894T patent/ES2433476T3/es not_active Expired - Lifetime
- 2001-01-19 ES ES06121895T patent/ES2301142T3/es not_active Expired - Lifetime
- 2001-01-19 PT PT06121895T patent/PT1741446E/pt unknown
- 2001-01-19 EP EP06121896.2A patent/EP1741447B1/de not_active Expired - Lifetime
- 2001-01-19 AT AT06121895T patent/ATE385421T1/de active
- 2001-01-19 EP EP06121898.8A patent/EP1743655B1/de not_active Expired - Lifetime
- 2001-01-19 DE DE122008000018C patent/DE122008000018I1/de active Pending
- 2001-01-19 BR BRPI0107715A patent/BRPI0107715B8/pt not_active IP Right Cessation
- 2001-01-19 PT PT61218947T patent/PT1741445E/pt unknown
- 2001-01-19 PT PT61218962T patent/PT1741447E/pt unknown
- 2001-01-19 DE DE60124861T patent/DE60124861T2/de not_active Expired - Lifetime
- 2001-01-19 CA CA002397554A patent/CA2397554C/en not_active Expired - Lifetime
- 2001-01-19 DK DK01909661.9T patent/DK1248604T4/da active
- 2001-01-19 CN CN01803953A patent/CN1400908A/zh active Pending
- 2001-01-19 EP EP06121894.7A patent/EP1741445B1/de not_active Expired - Lifetime
- 2001-01-19 DK DK06121898.8T patent/DK1743655T3/da active
- 2001-01-19 EP EP06121895A patent/EP1741446B1/de not_active Expired - Lifetime
2006
- 2006-07-10 JP JP2006189416A patent/JP2006273873A/ja active Pending
- 2006-12-29 CY CY20061101859T patent/CY1106303T1/el unknown
2008
- 2008-04-24 CY CY20081100459T patent/CY1107423T1/el unknown
- 2008-05-09 LU LU91436C patent/LU91436I2/fr unknown
- 2008-05-12 CY CY200800010C patent/CY2008010I2/el unknown
- 2008-05-14 NL NL300346C patent/NL300346I1/nl unknown
- 2008-05-14 FR FR08C0017C patent/FR08C0017I2/fr active Active
2011
- 2011-03-02 JP JP2011045331A patent/JP5835910B2/ja not_active Expired - Lifetime
- 2011-03-30 JP JP2011076253A patent/JP5824224B2/ja not_active Expired - Lifetime
2013
- 2013-10-09 CY CY20131100877T patent/CY1114466T1/el unknown
- 2013-11-08 CY CY20131100996T patent/CY1114593T1/el unknown
2014
- 2014-02-06 JP JP2014020963A patent/JP6095589B2/ja not_active Expired - Lifetime
- 2014-08-08 CY CY20141100633T patent/CY1115449T1/el unknown
2015
- 2015-07-31 JP JP2015151372A patent/JP6104331B2/ja not_active Expired - Lifetime
2017
- 2017-01-19 JP JP2017007638A patent/JP6374995B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2397554A1 (en)	2001-07-26
JP2017081994A (ja)	2017-05-18
EP1741445B1 (de)	2013-08-14
JP6104331B2 (ja)	2017-03-29
ES2275654T5 (es)	2012-06-07
EP1743655A1 (de)	2007-01-17
CN1977842A (zh)	2007-06-13
LU91436I9 (de)	2019-01-02
JP5835910B2 (ja)	2015-12-24
PT1741447E (pt)	2013-12-11
BRPI0107715B8 (pt)	2021-05-25
DK1741446T3 (da)	2008-06-02
PT1248604E (pt)	2007-01-31
AU2001237321A1 (en)	2001-07-31
CN102327614A (zh)	2012-01-25
JP6095589B2 (ja)	2017-03-15
CY1107423T1 (el)	2010-07-28
FR08C0017I1 (de)	2008-07-18
DK1248604T3 (da)	2007-02-19
EP1741445A2 (de)	2007-01-10
CY1115449T1 (el)	2017-01-04
DE60124861T2 (de)	2007-05-10
CY1114466T1 (el)	2016-10-05
DK1741445T3 (da)	2013-11-04
CA2673615A1 (en)	2001-07-26
HK1102422A1 (en)	2007-11-23
JP2011116772A (ja)	2011-06-16
JP2011162550A (ja)	2011-08-25
PT1741445E (pt)	2013-11-11
DE60132723T2 (de)	2009-01-29
ES2275654T3 (es)	2007-06-16
NL300346I1 (de)	2008-07-01
WO2001052825A3 (en)	2002-03-28
DE60124861D1 (de)	2007-01-11
DK1743655T3 (da)	2014-08-18
HK1102424A1 (en)	2007-11-23
BR0107715A (pt)	2002-11-19
JP5824224B2 (ja)	2015-11-25
CY2008010I1 (el)	2009-11-04
JP2003520226A (ja)	2003-07-02
PT1743655E (pt)	2014-09-09
CN1400908A (zh)	2003-03-05
CY1106303T1 (el)	2011-10-12
ATE385421T1 (de)	2008-02-15
CA2673615C (en)	2013-07-16
DE60132723D1 (de)	2008-03-20
US20030139434A1 (en)	2003-07-24
JP2014088435A (ja)	2014-05-15
EP1741445A3 (de)	2007-01-24
CY1114593T1 (el)	2016-10-05
HK1108359A1 (en)	2008-05-09
JP6374995B2 (ja)	2018-08-15
JP2015214572A (ja)	2015-12-03
JP2006273873A (ja)	2006-10-12
EP1741446B1 (de)	2008-02-06
ES2301142T3 (es)	2008-06-16
EP1741447B1 (de)	2013-09-18
DK1741447T3 (da)	2013-12-09
ES2436610T3 (es)	2014-01-03
EP1248604B1 (de)	2006-11-29
CA2397554C (en)	2009-09-22
EP1743655B1 (de)	2014-06-25
BRPI0107715B1 (pt)	2016-07-05
CY2008010I2 (el)	2009-11-04
EP1248604A2 (de)	2002-10-16
EP1741446A3 (de)	2007-01-17
EP1248604B2 (de)	2012-02-29
EP1741446A2 (de)	2007-01-10
ATE346613T1 (de)	2006-12-15
PT1741446E (pt)	2008-05-09
EP1741447A2 (de)	2007-01-10
WO2001052825A2 (en)	2001-07-26
DK1248604T4 (da)	2012-05-21
EP1741447A3 (de)	2007-01-17
ES2433476T3 (es)	2013-12-11
ES2487897T3 (es)	2014-08-25
LU91436I2 (fr)	2008-07-09
HK1102405A1 (en)	2007-11-23
FR08C0017I2 (fr)	2010-12-31

Publication	Publication Date	Title
DE60132723D1 (de)	2008-03-20	Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US7981918B2 (en)	2011-07-19	Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US7485641B2 (en)	2009-02-03	Substituted 3-amino-pyrrolidino-4-lactams
WO2006070195A8 (en)	2006-08-24	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
ZA200500816B (en)	2006-07-26	Aza-bicycloalkyl ethers and their use as alpha7-bacgr agonist
WO2004048345A3 (en)	2004-07-15	2,5-diketopiperazines for the treatment of obesity
MXPA05000896A (es)	2005-04-19	Derivados de 2-ciano-4-fluoropirrolidina o su sal.
BRPI0518409A2 (pt)	2008-11-18	combinaÇço de inibidor dpp-iv, antidiabÉtico ppar e metformina
CA2432799A1 (en)	2002-06-27	Pyrazole compounds useful as protein kinase inhibitors
JP2010537969A (ja)	2010-12-09	置換キノキサリンタイプピペリジン化合物とその使用
WO2006104997A3 (en)	2006-12-21	Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
AU2003229548A1 (en)	2003-09-09	Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
WO2006084757A3 (en)	2006-11-23	Combination of ca/mg salt of valsartan with an antidiabetic agent
WO2004039775A3 (en)	2004-08-26	Il-8 receptor antagonists
TW200606961A (en)	2006-02-16	Ceramic electronic parts and method for manufacturing ceramic electronic parts